Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28748508 | 0.89 | SCN5A (0.40) | SCN5ASCN9ASCN10A | |
| SCHEMBL249258 | 0.88 | SCN5A (0.47) | SCN5ASCN9ASCN10A | |
| SCHEMBL249257 | 0.88 | SCN5A (0.47) | SCN5ASCN9ASCN10A | |
| SCHEMBL17533289 | 0.86 | SCN5A (0.39) | SCN5ASCN9ASCN10A | |
| SCHEMBL17533287 | 0.86 | SCN5A (0.39) | SCN5ASCN9ASCN10A | |
| SCHEMBL1952758 | 0.83 | SCN5A (0.58) | SCN5ASCN9ASCN10A | |
| SCHEMBL561223 | 0.82 | TSHR (0.47) | SCN5ASCN9ASCN10A | |
| SCHEMBL1927023 | 0.82 | SCN5A (0.49) | SCN5ASCN9ASCN10A | |
| SCHEMBL4023092 | 0.82 | SCN5A (0.49) | SCN5ASCN9ASCN10A | |
| SCHEMBL19236698 | 0.81 | SCN5A (0.49) | SCN5ASCN9ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3218345-A | — | — | None | — | — | JP | disclosed |
| EP-3153499-B1 | METHOD FOR PRODUCING N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2018-09-19 | — | — | EP | disclosed |
| EP-3153499-A1 | METHOD FOR PRODUCING N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2017-04-12 | — | — | EP | disclosed |
| EP-3153500-A1 | METHOD FOR PRODUCING ISOCYANATE USING N-SUBSTITUTED CARBAMIC ACID ESTER, AND COMPOSITION FOR TRANSFERRING AND STORING N-SUBSTITUTED CARBAMIC ACID ESTER CONTAINING N-SUBSTITUTED CARBAMIC ACID ESTER AND AROMATIC HYDROXY COMPOUND | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2017-04-12 | — | — | EP | disclosed |
| CN-103781472-B | Synthesis and use of propofol glycoside derivatives | 纽泰克制药有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-9023813-B2 | Synthesis and use of glycoside derivatives of propofol | NuTek Pharma Ltd. (US) | 2015-05-05 | — | — | US | disclosed |
| CN-103781472-A | Synthesis and use of propofol glycoside derivatives | NUTEK PHARMA LTD | 2014-05-07 | — | — | CN | disclosed |
| CN-103702670-A | Synthesis and use of glycoside pro-drug analogs | NUTEK PHARMA LTD | 2014-04-02 | — | — | CN | disclosed |
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-11-22 | — | — | US | disclosed |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | NuTek Pharma Ltd. | 2012-10-18 | — | — | US | disclosed |
| WO-2012142147-A2 | SYNTHESIS AND USE OF GLYCOSIDE DERIVATIVES OF PROPOFOL | NuTek Pharma Ltd. (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012142141-A1 | SYNTHESIS AND USE OF GLYCOSIDE PRO-DRUG ANALOGS | NuTek Pharma Ltd. (US) | 2012-10-18 | — | — | WO | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| JP-H03218345-A | ACAT INHIBITOR | WARNER LAMBERT CO | 1991-09-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295866-A1 | Synthesis And Use Of Glycoside Pro-Drug Analogs | GCG, CYP3A5, UGT1A6 | SCN5A 1423/4885SCN9A 3539/4885SCN10A 2714/4885 |
| US-20120264702-A1 | Synthesis And Use Of Glycoside Derivatives of Propofol | CYP3A5, CYP3A4, UGT1A4 | SCN5A 529/4885SCN9A 2695/4885SCN10A 1554/4885 |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | SCN5A 1393/4885SCN9A 2164/4885SCN10A 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.